Tag: wall street journal

wall street journal

Kamp to WSJ: FDA Could Do a Better Job of Defending Off-label Limits

March 31, 2014 – The FDA’s recent draft guidance on disseminating reprints, textbooks and clinical practice guidelines (CPGs) discussing off-label uses is a “baby step” forward, Coalition for Healthcare Communication Executive Director John Kamp told The Wall Street Journal (WSJ) last week. In a March 25 WSJ “Corporate Intelligence” blog post written by former Pharmalot […]

Read more